EU/3/19/2160

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2160) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic skin-derived ABCB5-positive mesenchymal stem cells (also known as allo-APZ2-EB) for the treatment of epidermolysis bullosa.

Key facts

Active substance
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2160

Sponsor's contact details

RHEACELL GmbH & Co. KG
Im Neuenheimer Feld 517
69120 Heidelberg
Germany
Tel. +49 6221 718330
E-mail: office@rheacell.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating